Latest Leadership News

Ballard Mining Limited has released a comprehensive investor update following its July 2025 IPO, highlighting a robust 1.1 million ounce gold resource at Mt Ida and a strong cash position of $40 million. The company outlines ambitious exploration targets and development plans aiming to extend mine life beyond a decade.

ANZ reported a 10% decline in statutory profit for FY2025, impacted by significant regulatory and restructuring charges, while reaffirming its ANZ 2030 strategy and maintaining a strong capital position.

Invex Therapeutics Ltd has been suspended from trading on the ASX due to a failure to maintain the minimum number of directors required by law. The suspension will remain until the company rectifies its governance structure and complies with listing rules.

Epsilon Healthcare has posted its highest-ever quarterly receipts of $2.919 million, reflecting a robust turnaround since exiting voluntary administration in mid-2024. The company’s strategic sale and leaseback deal has also enabled significant debt reduction, setting the stage for sustained growth.

Epsilon Healthcare has commenced operations of its new pharmacy division and extended a key loan facility, signaling a strategic pivot towards integrated healthcare and financial stability after recent restructuring.

TT Investments has launched an unconditional $0.31 per security takeover bid for 360 Capital Group, aiming to delist the company from the ASX. The Independent Board Committee recommends acceptance amid significant premiums and looming governance changes.

Lithium Universe has signed a strategic MOU with Taiwan’s RePV Tech to collaborate on advanced silver extraction from recycled solar panels, aiming to transform photovoltaic waste into valuable resources.

Nine Entertainment reported a resilient FY25 with strategic transformation gains, digital subscription growth, and a major capital return following the sale of its Domain stake. Leadership changes and regulatory challenges frame its path forward.

REA Group reported a solid start to FY26 with 4% revenue growth and a key acquisition that enhances its AI-driven property technology portfolio. Despite challenges in India, the Australian market’s strong yield growth and product adoption underpin a confident outlook.

AVITA Medical reported an 18% revenue increase in Q3 2025 driven by new product launches and deeper market penetration, while continuing to face net losses and credit covenant challenges. The company also announced a CEO departure and interim leadership appointment.

The Calmer Co. International Limited announces a leadership change with James S. Tonkin appointed Chairman as the company accelerates its U.S. market growth in natural kava products.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.